The key takeaways for this program are:
- Understanding the Prometheus decision and what the Supreme Court did and did not say;
- Understanding the question at issue in Myriad and how it is similar—and different—from that decided in Prometheus;
- Learning possible patent claim strategies to protect personalized medicine methods and biotechnology inventions under the new paradigm;
- Reviewing the U.S. Patent Office Guidance to Examiners, issued shortly after the Supreme Court decided Prometheus; and
- Discussing Options for strengthening already granted patents.
People
Related Insights
April 17, 2026
Manufacturing Industry Advisor
Virginia Bans Post-Term Non-Compete Provisions in Franchise Agreements
On April 13, 2026, Governor Abigail Spanberger signed legislation amending the Virginia Retail Franchising Act. House Bill 69 and its…
April 17, 2026
Foley Viewpoints
Texas Attorney General Investigates Lululemon Over Alleged “Forever Chemicals” in Activewear. What This Signals for Consumer Products, Apparel, and Wellness Brands
Summary The Texas Attorney General (AG) has issued a Civil Investigative Demand to Lululemon USA Inc. (Lululemon) to examine whether the…
April 16, 2026
Manufacturing Industry Advisor
Foley Automotive Update
Foley is here to help you through all aspects of rethinking your long-term business strategies, investments, partnerships, and technology. Contact the authors, your Foley relationship partner, or our Automotive Team to discuss and learn more.